Tisagenlecleucel In Primary CNS Lymphoma

Inclusion Criteria: Primary CNS Lymphoma in high risk elderly patients * New diagnosis of primary CNS lymphoma. * Voluntarily sign informed consent form(s) * ≥60 years of age at the time of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * Have failed or are unable to tolerate definitive first-line methotrexate based therapy as defined by: * Grade 3+ AKI and/or transaminitis preventing repeat treatment exposure and/or, * Failure to achieve a complete response (per IPCG) following two cycles of first line therapy, \--- Definitive first-line therapies must include high dose methotrexate-based therapy but may also include temozolomide, high dose cytarabine, pemetrexed, lenalidomide, ibrutinib and rituximab. * Whole-brain irradiation, lenalidomide monotherapy and ibrutinib monotherapy are considered first line therapy if patient was not eligible for methotrexate-based chemotherapy at time of initial treatment but now meets study eligibility criteria. * Adequate absolute lymphocyte count (ALC \> 500 cells/ul) within one week of apheresis. * Adequate bone marrow function defined by absolute neutrophil count (ANC) \>1000 cells/mm3without growth factor support, and untransfused platelet count \>50,000 mm3 within 7 days. * Left ventricular ejection fraction \>40% * Adequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \<2.5 × upper limit of normal (ULN) and direct bilirubi…